[A25-65] Glofitamab (DLBCL, monotherapy, third line or later) – Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2025
Project no.:
A25-65
Commission:
Commission awarded on 14.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with relapsed or refractory diffuse large B-cell lymphoma, after 2 or more lines of systemic therapy
Result of dossier assessment:
- Patients who are eligible for CAR T-cell therapy or stem cell transplantation: added benefit not proven
- Patients who are ineligible for CAR T-cell therapy and stem cell transplantation: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-65
| Project no. | Title | Status |
|---|---|---|
| G23-17 | Glofitamab (diffuse large B-cell lymphoma) – Assessment according to § 35a Social Code Book (SGB) V (1) Sentence 11 | Commission completed |
| A25-64 | Glofitamab (DLBCL, combination with gemcitabine and oxaliplatin) – Benefit assessment according to §35a Social Code Book V | Commission completed |